-
Mashup Score: 1
Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #rarediseases #XORTX https://t.co/WcCkqgoQKG
-
-
Mashup Score: 0What Is Autosomal Dominant Polycystic Kidney Disease (ADPKD)? - 1 year(s) ago
Dr. Allen Davidoff, CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease (ADPKD).
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allen Davidoff, Ph.D., CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #raredisease https://t.co/6rUqGAHy6K
-
-
Mashup Score: 0
Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #rarediseases #XORTX https://t.co/WcCkqgoQKG
-
-
Mashup Score: 0What Is Autosomal Dominant Polycystic Kidney Disease (ADPKD)? - 1 year(s) ago
Dr. Allen Davidoff, CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease (ADPKD).
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allen Davidoff, Ph.D., CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #raredisease https://t.co/6rUqGAHy6K
-
-
Mashup Score: 0What Is Autosomal Dominant Polycystic Kidney Disease (ADPKD)? - 1 year(s) ago
Dr. Allen Davidoff, CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease (ADPKD).
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Allen Davidoff, Ph.D., CEO of XORTX Therapeutics, gives an overview of autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #raredisease https://t.co/6rUqGAHy6K
-
-
Mashup Score: 0Is Metformin Now in Our Armamentarium for Autosomal Dominant Polycystic Kidney Disease (ADPKD)? - 1 year(s) ago
Orhan Efe @OrhanEfe_ Dr. Orhan Efe is a Nephrologist at Massachusetts General Hospital in Boston, MA. Dr. Efe was an AJKD Editorial Intern from 2021-2022. He is passionate about glomerular diseases…
Source: AJKD BlogCategories: Latest Headlines, NephrologyTweet-
Counting down the Top Ten #AJKDBlog posts of 2022: 3. Is Metformin Now in Our Armamentarium for Autosomal Dominant Polycystic Kidney Disease? by @OrhanEfe_ and Jeff M. Sands https://t.co/r2AlbMSHiN #ADPKD https://t.co/ZvTtKyK2yG
-
-
Mashup Score: 1Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney Disease - 1 year(s) ago
This retrospective study assesses the prevalence of autosomal dominant polycystic kidney disease and contributions of PKD1, PKD2, and other genes related to cystic kidney disease in a large, unselected cohort of patients.
Source: jamanetwork.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic #KidneyDisease https://t.co/GBRdoJoyZ8 via @JAMA_current part of @JAMANetwork #PKD #ADPKD #PKD1 #PKD2 https://t.co/tZGlSSi01L
-
-
Mashup Score: 1
UC San Diego Health has been named a Center of Excellence for polycystic kidney disease (PKD) by the PKD Foundation – the leading advocacy group dedicated to finding treatments and a cure for PKD. UC San Diego Health is one of just 28 institutions nationwide to receive this designation.
Source: today.ucsd.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to lead the @ucsdnephrology #ADPKD Center of Excellence. Thanks @PKDFoundation for this designation and the @UCSDHealth team for making this possible. Look forward to providing high level, comprehensive, multi-disciplinary care. @PKDFSanDiego https://t.co/ShwzWpICeg
-
-
Mashup Score: 3
Tolvaptan is associated with risk of drug-induced liver injury (DILI) when used to treat autosomal dominant polycystic kidney disease (ADPKD). After this risk was described based on the clinical trials TEMPO 3:4 and TEMPO 4:4, additional data from the REPRISE Study and a long-term extension of TEMPO 4:4, REPRISE, and other tolvaptan trials in ADPKD have become available. To further characterize…
Categories: Latest Headlines, NephrologyTweet-
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With #ADPKD: An Analysis of Pivotal Clinical Trials https://t.co/dhH6qhYQSB #OpenAccess @lucasmembrane #visualabstract https://t.co/Tazk65I1Uo
-
Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #rarediseases #XORTX https://t.co/WcCkqgoQKG